IL10 and metabolic dysfunction-associated steatohepatitis: It is also known that IL-10 exhibits therapeutic effects in various fibrotic diseases, including IPF and nonalcoholic steatohepatitis, by inhibiting the pro-fibrotic signaling pathway [107, 108].